DeepMed Research

Agatolimod

Generic Name: Agatolimod

Drug Type: Biotech

CAS Number: 207623-20-9

Unique Ingredient Identifier: 5V336PV3HG

Background: Agatolimod is under investigation in clinical trial NCT00471471 (Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery).

Clinical Trials

A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

Phase 2

Completed

Conditions: Lymphomas: Non-Hodgkin
Lymphoma, Non-Hodgkin
Lymphoma
Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell

Interventions: Drug: PF-3512676
Radiation: Local radiotherapy

First Posted Date: 2009-04-14

Last Posted Date: 2017-03-14

Lead Sponsor: Ronald Levy

Target Recruit Count: 30

Registration Number: NCT00880581

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab
Drug: PF03512676
Other: Correlative Studies

First Posted Date: 2009-01-19

Last Posted Date: 2016-01-14

Lead Sponsor: Bhuvaneswari Ramaswamy

Target Recruit Count: 6

Registration Number: NCT00824733

Locations: 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants

Phase 1

Completed

Conditions: Nonneoplastic Condition

Interventions: Biological: PADRE-CMV fusion peptide vaccine
Biological: tetanus-CMV fusion peptide vaccine
Drug: agatolimod sodium

First Posted Date: 2008-07-28

Last Posted Date: 2012-06-25

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 68

Registration Number: NCT00722839

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.

Phase 2

Withdrawn

Conditions: Breast Neoplasms

First Posted Date: 2007-05-09

Last Posted Date: 2015-05-04

Lead Sponsor: Pfizer

Registration Number: NCT00471159

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Nodal Marginal Zone Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Recurrent Grade 2 Follicular Lymphoma
Waldenstrom Macroglobulinemia
Recurrent Marginal Zone Lymphoma
Adult Non-Hodgkin Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma

Interventions: Drug: Agatolimod Sodium
Radiation: Indium In-111 Ibritumomab Tiuxetan
Other: Laboratory Biomarker Analysis
Procedure: Radionuclide Imaging
Biological: Rituximab
Procedure: Single Photon Emission Computed Tomography
Radiation: Yttrium Y-90 Ibritumomab Tiuxetan

First Posted Date: 2007-02-22

Last Posted Date: 2016-02-04

Lead Sponsor: Mayo Clinic

Target Recruit Count: 38

Registration Number: NCT00438880

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States

Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC

Phase 3

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Cisplatin
Drug: Gemcitabine + Cisplatin
Drug: Gemcitabine
Drug: PF-3512676

First Posted Date: 2005-11-17

Last Posted Date: 2015-03-30

Lead Sponsor: Pfizer

Target Recruit Count: 839

Registration Number: NCT00254904

Locations: 🇬🇧
Pfizer Investigational Site, Wolverhampton, United Kingdom

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Phase 2

Completed

Conditions: Recurrent Intraocular Melanoma
Recurrent Melanoma
Stage IIIC Melanoma
Ciliary Body and Choroid Melanoma, Small Size
Stage IIIA Melanoma
Stage IIIB Intraocular Melanoma
Extraocular Extension Melanoma
Iris Melanoma
Ciliary Body and Choroid Melanoma, Medium/Large Size
Stage IIIB Melanoma

Interventions: Biological: gp100 antigen
Biological: tyrosinase peptide
Biological: recombinant MAGE-3.1 antigen
Biological: multi-epitope melanoma peptide vaccine
Biological: incomplete Freund's adjuvant
Drug: Montanide ISA 51 VG
Drug: agatolimod sodium
Other: laboratory biomarker analysis

First Posted Date: 2004-06-11

Last Posted Date: 2014-05-22

Lead Sponsor: University of Southern California

Target Recruit Count: 42

Registration Number: NCT00085189

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States

Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-19

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00040950

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

Phase 2

Completed

Conditions: Melanoma
Breast Neoplasms
Carcinoma, Renal Cell
Lymphoma, T-Cell
Carcinoma, Non-Small-Cell Lung

Interventions: Drug: PF-3512676

First Posted Date: 2002-08-12

Last Posted Date: 2009-03-12

Lead Sponsor: Pfizer

Target Recruit Count: 31

Registration Number: NCT00043368

Locations: 🇩🇪
Pfizer Investigational Site, Koeln, Germany

CPG 7909 in Patients With Cutaneous T-Cell Lymphoma

Phase 1

Completed

Conditions: Lymphoma, T-Cell, Cutaneous

Interventions: Drug: PF-3512676

First Posted Date: 2002-08-12

Last Posted Date: 2009-02-12

Lead Sponsor: Pfizer

Target Recruit Count: 42

Registration Number: NCT00043420

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy